The Lancet Oncology : Impact Factor & More
eISSN: 1474-5488pISSN: 1470-2045
Share this on:
Key Metrics
CiteScore 
56.9
Eigenfactor
0.1 - 0.5
H-Index
382
Impact Factor
>= 25
Scite Index
0.86 5-Year SI
SJR
Q1Oncology
SNIP
11.42
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on The Lancet Oncology
The Lancet Oncology Journal Specifications
| Overview | |
| Publisher | ELSEVIER SCIENCE INC |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 2000 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in The Lancet Oncology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in The Lancet Oncology
Real-world heart and lung doses from 30 000 National Health Service radiotherapy treatment plans in England: a national audit of breast radiotherapy practice.
- 18 May 2026
- The Lancet. Oncology
OncoCorridor: connecting patients with cancer in conflict zones to treatment centres worldwide.
- 18 May 2026
- The Lancet. Oncology
Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study.
- 17 May 2026
- The Lancet. Oncology
Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials.
- 17 May 2026
- The Lancet. Oncology
MRI-guided adaptive radiotherapy for high grade glioma (UNITED): a single-centre, single-arm, non-inferiority, phase 2 trial.
- 14 May 2026
- The Lancet. Oncology
Reshaping breast cancer radiotherapy after FAST-Forward.
- 14 May 2026
- The Lancet. Oncology
Real-world heart and lung doses from 30 000 National Health Service radiotherapy treatment plans in England: a national audit of breast radiotherapy practice.
- 18 May 2026
- The Lancet. Oncology
OncoCorridor: connecting patients with cancer in conflict zones to treatment centres worldwide.
- 18 May 2026
- The Lancet. Oncology
Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study.
- 17 May 2026
- The Lancet. Oncology
Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials.
- 17 May 2026
- The Lancet. Oncology
MRI-guided adaptive radiotherapy for high grade glioma (UNITED): a single-centre, single-arm, non-inferiority, phase 2 trial.
- 14 May 2026
- The Lancet. Oncology
Reshaping breast cancer radiotherapy after FAST-Forward.
- 14 May 2026
- The Lancet. Oncology
FAQs on The Lancet Oncology
How long has The Lancet Oncology been actively publishing? 
What is the publishing frequency of The Lancet Oncology?
How many articles did The Lancet Oncology publish last year?
What is the eISSN & pISSN for The Lancet Oncology?
What is Citescore for The Lancet Oncology?
What is the H Index for The Lancet Oncology ?
What is SNIP score for The Lancet Oncology?
What is the SJR for The Lancet Oncology?
Who is the publisher of The Lancet Oncology?
